Pacific Biosciences Of California (PACB) Common Equity (2010 - 2026)

Pacific Biosciences Of California's Common Equity history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Common Equity fell 97.42% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 97.42% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 98.94% from the prior year.
• Common Equity retreated to $2.4 million in Q1 2026 per PACB's latest filing, from $5.3 million in the prior quarter.
• Across five years, Common Equity topped out at $763.7 million in Q3 2023 and bottomed at $2.4 million in Q1 2026.
• The 5-year median for Common Equity is $562.9 million (2022), against an average of $453.1 million.
• Across the five-year window, Common Equity jumped 10133.4% in 2022 and slumped 98.94% in 2025, its largest moves.
• Year by year, Common Equity stood at $562.9 million in 2022, then grew by 24.59% to $701.3 million in 2023, then slipped by 27.76% to $506.6 million in 2024, then slumped by 98.94% to $5.3 million in 2025, then plunged by 55.77% to $2.4 million in 2026.
• Per Business Quant, the three latest PACB Common Equity figures stand at $2.4 million (Q1 2026), $5.3 million (Q4 2025), and $36.1 million (Q3 2025).